In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic collagen-induced arthritis model a pre-clinical study
genesis induced by VEGF.
Fig. 7. GW856553X inhibits angio-
Angiogenesis (1ng/ml) was assessed after 11 days. in response to VEGF (using alkaline phosphatase-mediated a) CD31 expression was measured conversion colorimetric of ± assay. p-NPP Data followed are by experiments, SD, representative 1-way and were of 3 similar means the ANOVA versus analysed response by in **
shows p<0.01, absence ***of p<0.001. inhibitor: Dashed *p<0.05, line cells. showing morphology of the formed (b-d)release Representative from unstimulated images tubes following stained for CD31 at day dium alone, (stimulation plus 100nM GW856553X (objective


c) VEGF or (with d() VEGF b) me-11, magni cation ×40).
(32). The invention of these p38 MAP kinase humans for e t but also to reduce adverse effects.
and enhance patient’s ben-human treating compounds or reducing provides symptoms methods in Lastly and not least the amounts of the tokine-driven or animals suffering from cy-inhibitors, the timing(s) of administra-such as rheumatoid arthritis, and many in ammatory diseases tion, other age the form of the compound, the dependent in ammatory or putative p38 treatment and the therapies are also considered, in order diseases (5). Combination to assess their bene t in the clinic. Po-should medical be important condition factors under to adapt treatment modalities to the tential non-steroid anti-in ammatory drugs is
limitations for the use of these 184
to prevent or treat the aforementioned clinical activity conditions lead to unwanted side effects, and their of Cox enzymes, are their which inhibition can limitation Third generation of p38 MAPK inhibi-in CNS penetration (33). tors that are currently in clinical trials will eventually permit a better charac-terisation of the role of p38 MAPK in humans selectivity pro les.
by virtue of improved kinase The lapsing inhibition of geted GSK678361, compounds, arthritis by murine p38 MAPK chronic tar-re-present study indicates that p38 MAPK as demonstrated GW856553X in and the inhibition RA may have therapeutic potential for as a therapeutic target for future use in RA if safe clinical dosing achieves adequate compound exposure. Acknowledgements
We are grateful to the staff of the Bio-logical tute of Rheumatology, Imperial College Services Unit (Kennedy Insti- London, UK) for their help in the care and maintenance of laboratory mice used in our studies; and to the Histopathology Department, London, for the sectioning and staining Charing Cross Hospital, of paw specimens. The Kennedy Insti-tute of Rheumatology is supported by the Arthritis Britain (arc). The authors also thank Ri-Research Campaign of Great chard Williams, Mino Medghalchi, Ian Buysschaert and Nasser Malik for their assistance in the in vivo studies.
1. References
FAROOQ A, lation of MAPK ZHOU phosphatases. MM: Structure Cell and Signal regu- 2. 2004, 16: 769-79.
KAMINSKA as B: MAPK therapy--from molecular targets signalling pathways
therapeutic bene ts. molecular for anti-in ammatory Biochim mechanisms Biophys Acta to 3. 2005, 1754: 253-62.
BAINBRIDGE J, MADDEN L, ESSEX D, BINKS
M, nine MALHOTRA R, PALEOLOG EM: Methio-chronic aminopeptidase-2 role for angiogenesis inhibition. collagen-induced blockade arthritis: potential reduces 4. Ther MALFAIT 2007, 9: R127.
Arthritis Res MAINI AM, WILLIAMS RO, MALIK ing homologous collagen-induced arthritis in RN, FELDMANN M: Chronic relaps-AS,
DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies. 5. Arthritis Rheum ASTON NM, BAMBOROUGH P, BUCKTON JB
2001, 44: 1215-24.
et al.: p38alpha mitogen-activated protein
p38 inhibition and not MK2 inhibition enhances ...efficacy in in vitro and in vivo inflammatory ... Novel inhibitor of p38 MAP kinase as an anti...
(2013) In Vitro and In Vivo Experimental Models...Efficacy of Antineoplastic Drugs on Urinary Bladder...inhibition are the oldest and most commonly used ...
The potent anti-leukemia efficacy of Icaritin in murine model demonstrated ... Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a...
of 4T1 breast cancer in vitro and in vivo. ...In vivo growth-inhibition of Sarcoma 180 by ...Chemopreventive efficacy of curcumin and piperine ...
namely stimulation of osteoblastic cell proliferation and inhibition of ...In summary, the present study clearly demonstrates the in vivo efficacy of ...
Experimental models of elevated Pgc in vivo ...In vitro mechanical stimulation therefore represents ...of p38 MAP kinase and subsequent inhibition by ...
Target validation Seattle/Chicago: Structure ...(in vitro systems) Biochemical (kinase, protease,...Inhibition Slide 20 deCODE Capabilities: In Vivo ...
In vitro models (enzyme inhibition, receptor ...and in silico) Bottleneck: Target validation, “... www.kubinyi.de MAP Kinase Pathways Kinases www....
[1] Target: p38 MAPK in vitro: In SHR-SPs receiving a salt-fat diet...Analgesic efficacy and safety of the novel p38 MAP kinase inhibitor, ...
Efficacy of a Tyrosine... 暂无评价 9页 免费 ...in vitro screening for tyrosine kinase inhibitors ...Also, there is substantial in vivo inhibition of...
热门文档